Search Results
MRD-guided therapy in patients with intermediate-risk AML compared to unguided cohort using PSM
Implementing MRD in clinical practice for patients with intermediate-risk AML
Treatment of intermediate-risk AML with gemtuzumab ozogamicin
When should patients with intermediate-risk AML be indicated for alloSCT?
An insight into MRD monitoring and MRD-driven treatment in AML
The role of MRD in AML
The role of allogeneic transplantation in patients with AML in the frontline setting
Determining the most suitable consolidation therapies for AML by defining patient risk group
MRD conversion rate with consolidation chemotherapy in AML
How can serial MRD monitoring be utilized to improve relapse outcomes?
The future of AML treatment
V-FAST subgroup analysis: CPX-351 plus midostaurin for newly diagnosed FLT3-mutated AML
